Rh negative blood group and methergin in LSCS
Reading File
Finding Sources
Finding Sources
Searching PubMed
Rh isoimmunization cesarean section anti-D
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
Rh negative blood group LSCS anti-D immunoglobulin methergin methylergometrine contraindication
Searching the Web
methergin methylergometrine contraindicated Rh negative LSCS blood pressure uterotonic
Finding Sources
Reading Web Page
Rh negative contraindication methergin methylergometrine LSCS caesarean uterotonic
Searching the Web
why methergin avoided Rh negative mother LSCS active management third stage labour
I now have comprehensive information to give a thorough, well-sourced answer. Let me compile this.
Rh Negative Blood Group and Methergin (Methylergometrine) in LSCS
These are two distinct but important considerations that arise when managing an Rh negative mother undergoing a lower segment caesarean section (LSCS).
Part 1: Rh Negative Blood Group in LSCS
Why LSCS is a Sensitizing Event
LSCS is classified as a potentially sensitizing event - it causes significant fetomaternal hemorrhage (FMH) because:
- Surgical incision through the uterus disrupts the placental bed
- This allows fetal Rh(D)-positive red cells to enter the maternal circulation
- The risk of FMH is higher with LSCS compared to normal vaginal delivery (NVD)
If an Rh(D)-negative unsensitized mother carries an Rh(D)-positive baby and is not given anti-D prophylaxis, she has approximately 80% likelihood of developing anti-D alloantibodies after exposure (RhoGAM prescribing information). These IgG anti-D antibodies can cross the placenta in subsequent pregnancies and cause Hemolytic Disease of the Fetus and Newborn (HDFN).
Anti-D Immunoglobulin (RhIG) Protocol After LSCS
| Parameter | Details |
|---|---|
| Indication | All unsensitized Rh(D)-negative mothers delivering an Rh(D)-positive baby |
| Standard dose | 300 mcg (1500 IU) in USA; 625 IU (125 mcg) in Australia/UK post-delivery |
| Antenatal prophylaxis | 300 mcg at 28 weeks routinely; additional dose after LSCS |
| Timing | Must be given within 72 hours of delivery |
| Kleihauer-Betke test | Indicated post-LSCS to quantify FMH - if >30 mL fetal blood, additional RhIG doses are required (1 vial per 30 mL whole blood or 15 mL packed RBCs) |
Key points from the textbooks (Henry's Clinical Diagnosis and Management by Laboratory Methods):
- All Rh-negative women should receive RhIG prophylactically in midpregnancy, following any invasive procedure, and immediately after delivery
- RhIG should be given within 72 hours of exposure to prevent active immunization
- RhIG is not given to Rh-negative women who are already immunized (i.e., those who already have anti-D)
- Women with weak D types 1, 2, or 3 are NOT at risk for alloimmunization and do not require RhIG; women with partial D or other weak D genotypes should receive RhIG
What if the Baby is Rh Negative?
If the baby is confirmed Rh(D)-negative (cord blood typing), anti-D prophylaxis is not required.
Part 2: Methergin (Methylergometrine) in LSCS
Drug Overview
Methergin (methylergometrine maleate, 0.2 mg) is an ergot alkaloid uterotonic. It acts directly on uterine smooth muscle, inducing rapid, sustained tetanic contractions - shortening the third stage and reducing blood loss.
- IV onset: immediate
- IM onset: 2-5 minutes
- Oral onset: 5-10 minutes
Use in LSCS
Methergin is used in the active management of the third stage during LSCS to:
- Prevent/manage uterine atony
- Reduce postpartum hemorrhage
- Aid uterine involution after placental delivery
Contraindications - Especially Relevant to LSCS
| Contraindication | Reason |
|---|---|
| Hypertension / Preeclampsia / Toxemia | Strong vasoconstrictor - can trigger sudden severe hypertension, stroke, cerebrovascular accident |
| Pregnancy (before delivery) | Powerful uterotonic - causes fetal distress/death |
| Hypersensitivity | Anaphylaxis |
| Coronary artery disease | Coronary vasospasm, myocardial ischemia |
| CYP3A4 inhibitors (macrolides, azole antifungals, HIV protease inhibitors) | Ergotism risk |
IV administration should NOT be routine - it can cause sudden hypertensive crises. If IV is essential (life-saving), give very slowly over ≥60 seconds with BP monitoring (FDA label).
Why Rh Negative is Listed as an Exclusion for Methylergometrine Studies
One systematic review (Singh 2009, cited in Nguyen 2015, PCOM) listed "Rh- mother" in the exclusion criteria for methylergometrine RCTs. This is not because methergin itself is pharmacologically contraindicated in Rh negative women, but because:
- Tetanic uterine contractions caused by methylergometrine increase the squeeze effect on the placenta, potentially forcing more fetal blood into the maternal circulation - theoretically worsening FMH and raising the risk of Rh isoimmunization
- Rh negative mothers are a special-risk population requiring precise management and the researchers excluded them to reduce confounders in study populations
- From a clinical practice standpoint, in LSCS of Rh negative mothers, oxytocin is preferred as the first-line uterotonic because it does not cause vasoconstriction or tetanic contractions, and its action is more controlled
Practical Clinical Approach: Uterotonic Hierarchy in Rh-Negative LSCS
| Step | Drug | Notes |
|---|---|---|
| 1st line | Oxytocin (20 IU in 500 mL saline infusion, or 5 IU slow IV) | Safe, no vasoconstriction, well tolerated |
| 2nd line | Carboprost (PGF2α, 0.25 mg IM) | Use if oxytocin fails; avoid in asthma |
| 3rd line | Misoprostol (800 mcg sublingual/rectal) | Widely used in resource-limited settings |
| Methergin | 0.2 mg IM | Use only if normotensive; avoid if hypertensive or preeclamptic |
Key Summary Points for MCQ / Exam
- LSCS = sensitizing event - always give anti-D (RhIG 300 mcg) to unsensitized Rh-negative mothers within 72 hours if baby is Rh-positive
- Kleihauer-Betke test after LSCS to quantify FMH and determine if extra RhIG doses are needed
- Do not give RhIG if mother is already sensitized (has preformed anti-D)
- Methergin is contraindicated in hypertension/preeclampsia - a common co-morbidity in LSCS cases
- Methergin avoided in Rh-negative mothers in clinical trial protocols - due to concern over increased FMH from tetanic uterine contractions raising isoimmunization risk; oxytocin is preferred
- Methergin is not a standard FDA contraindication simply for Rh-negative blood type - but the clinical reasoning above makes oxytocin the safer choice
Sources: Henry's Clinical Diagnosis and Management by Laboratory Methods; RhoGAM Prescribing Information (FDA); Methergine (methylergonovine maleate) FDA label; Australian Rh D Immunoglobulin Guideline 2024; SOGC Rh and Alloimmunization guidelines; Nguyen, PCOM systematic review 2015
This is a shared conversation. Sign in to Orris to start your own chat.